Special Issue "Bioactive Compounds from Marine Microbes"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 July 2014

Special Issue Editor

Guest Editor
Dr. Kirk R. Gustafson
Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Building 562, Room 201, Frederick, MD 21702-1201, USA
Website: http://ccr.cancer.gov/staff/staff.asp?profileid=7125
E-Mail: gustafki@mail.nih.gov
Phone: +1 301 846 5197
Fax: +1 301 846 6157
Interests: natural products chemistry; chemical biology of natural products; NMR spectroscopy

Special Issue Information

Dear Colleagues,

The marine environment is a vast and largely unexplored resource for accessing diverse communities of microorganisms with novel biosynthetic capabilities. Marine habitats provide unique conditions for microbial growth and secondary metabolite expression that are not found in terrestrial ecosystems. The co-evolution of many marine macroorganisms, particularly invertebrate animals, with these microbes has often lead to the development of very close associations or symbiotic relationships between the host organism and a specific microbe. This in turn has resulted in the development and elaboration of unique microbial biosynthetic pathways and capabilities that can be utilized to generate novel compounds. Marine sediments are also now recognized as a rich source of microbial taxonomic diversity and new biologically active compounds. Efforts to cultivate and evaluate marine microorganisms and the associated compounds they can produce have expanded significantly in recent years, but this are of study is still very much in its infancy considering the vastness of the marine environment and the different types of microbial habitats found there.

Kirk R. Gustafson Ph. D.
Guest Editor

Keywords

  • actinomycetes
  • bacteria
  • biosynthesis
  • dereplication
  • fungi
  • metabolic modulators and elicitors
  • micro algae
  • quorum sensing
  • symbionts

Published Papers (13 papers)

Mar. Drugs 2014, 12(6), 3669-3680; doi:10.3390/md12063669
Received: 30 April 2014; in revised form: 3 June 2014 / Accepted: 13 June 2014 / Published: 20 June 2014
Show/Hide Abstract | PDF Full-text (864 KB) | HTML Full-text | XML Full-text | Supplementary Files
abstract graphic

Mar. Drugs 2014, 12(6), 3283-3291; doi:10.3390/md12063283
Received: 18 March 2014; in revised form: 8 May 2014 / Accepted: 16 May 2014 / Published: 30 May 2014
Show/Hide Abstract | Cited by 1 | PDF Full-text (614 KB) | HTML Full-text | XML Full-text | Supplementary Files
abstract graphic

Mar. Drugs 2014, 12(5), 2953-2969; doi:10.3390/md12052953
Received: 20 March 2014; in revised form: 22 April 2014 / Accepted: 25 April 2014 / Published: 16 May 2014
Show/Hide Abstract | PDF Full-text (769 KB) | HTML Full-text | XML Full-text | Supplementary Files

Mar. Drugs 2011, 9(10), 2155-2163; doi:10.3390/md9102155
Received: 19 July 2011; in revised form: 13 August 2011 / Accepted: 23 August 2011 / Published: 24 October 2011
Show/Hide Abstract | Cited by 2 | PDF Full-text (230 KB) | HTML Full-text | XML Full-text

Mar. Drugs 2011, 9(9), 1440-1468; doi:10.3390/md9091440
Received: 28 July 2011; in revised form: 11 August 2011 / Accepted: 15 August 2011 / Published: 25 August 2011
Show/Hide Abstract | Cited by 13 | PDF Full-text (1137 KB) | HTML Full-text | XML Full-text
abstract graphic

Mar. Drugs 2011, 9(8), 1391-1402; doi:10.3390/md9081391
Received: 10 July 2011; in revised form: 1 August 2011 / Accepted: 10 August 2011 / Published: 12 August 2011
Show/Hide Abstract | Cited by 9 | PDF Full-text (1758 KB) | HTML Full-text | XML Full-text | Supplementary Files

Mar. Drugs 2011, 9(8), 1346-1358; doi:10.3390/md9081346
Received: 25 June 2011; in revised form: 26 July 2011 / Accepted: 4 August 2011 / Published: 10 August 2011
Show/Hide Abstract | Cited by 5 | PDF Full-text (138 KB) | HTML Full-text | XML Full-text

Mar. Drugs 2011, 9(5), 832-843; doi:10.3390/md9050832
Received: 28 March 2011; in revised form: 20 April 2011 / Accepted: 4 May 2011 / Published: 12 May 2011
Show/Hide Abstract | Cited by 13 | PDF Full-text (332 KB) | HTML Full-text | XML Full-text | Supplementary Files

Mar. Drugs 2010, 8(4), 1153-1177; doi:10.3390/md8041153
Received: 6 February 2010; in revised form: 28 March 2010 / Accepted: 1 April 2010 / Published: 4 April 2010
Show/Hide Abstract | Cited by 21 | PDF Full-text (954 KB) | HTML Full-text | XML Full-text

Mar. Drugs 2010, 8(3), 705-727; doi:10.3390/md8030705
Received: 28 January 2010; in revised form: 26 February 2010 / Accepted: 16 March 2010 / Published: 17 March 2010
Show/Hide Abstract | Cited by 22 | PDF Full-text (196 KB) | HTML Full-text | XML Full-text

Mar. Drugs 2010, 8(3), 438-459; doi:10.3390/md8030438
Received: 18 January 2010; in revised form: 3 February 2010 / Accepted: 22 February 2010 / Published: 1 March 2010
Show/Hide Abstract | Cited by 42 | PDF Full-text (172 KB) | HTML Full-text | XML Full-text

Mar. Drugs 2009, 7(4), 624-639; doi:10.3390/md7040624
Received: 12 October 2009; in revised form: 18 November 2009 / Accepted: 19 November 2009 / Published: 23 November 2009
Show/Hide Abstract | Cited by 13 | PDF Full-text (279 KB) | HTML Full-text | XML Full-text
abstract graphic

Mar. Drugs 2009, 7(4), 497-522; doi:10.3390/md7040497
Received: 18 September 2009; in revised form: 28 October 2009 / Accepted: 29 October 2009 / Published: 2 November 2009
Show/Hide Abstract | Cited by 22 | PDF Full-text (249 KB) | HTML Full-text | XML Full-text
abstract graphic

Last update: 28 February 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert